TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01134549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Administered as a single intravenous (IV) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a single intravenous (IV) injection
Study: NCT02121184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine oxytocin
Description: per regular oxytocin protocols

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Half-dose oxytocin
Description: The dose of oxytocin currently being administered will be halved and not increased until after 60 minutes initiation of labor analgesia
Study: NCT01647828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-59R5
Description: OMP-59R5 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: administered intravenously
Study: NCT01237444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir plus one nucleoside
Description: ARM 1:~Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir /ritonavir plus two nucleosides
Description: ARM 2:~3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype.
Study: NCT04298086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Treatment
Description: Exercise treatment will consist of individualized walking delivered up to 7 times weekly to achieve the patient-specific goal energy expenditure. Training sessions will be performed on a treadmill at under remote surveillance using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-Based Diet
Description: Pre-prepared meals, including 6 dinners and 6 lunches per week, will be shipped to the partipant's home during the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Treadmills and low-calorie recipes will be provided to patients in the counseling arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition counseling
Description: Nutrition program including regular counseling by exercise physiologists and registered dieticians (RDs).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Replication Exercise Test
Description: Exercise capacity will be reassessed by a replication exercise test at week 6 in the intervention group only.
Study: NCT00004933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyurea
Description: 0.5 to 5 grams PO per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homoharringtonine
Description: 2.5 mg/ sq m/ day CIVI for 14 days
Study: NCT01293097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
Study: NCT02114203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDE9i
Description: oral dose, every 12 hours for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDE9i
Description: oral dose, every 12 hours for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for PDE9i
Description: oral dose, every 12 hours for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDE9i
Description: oral dose, every 12 hours for 28 days
Study: NCT04274465

Intervention type: DIAGNOSTIC_TEST
Intervention: digital PCR (dPCR) assay
Description: It is a highly sensitive and specific droplet digital PCR assay for absolute quantification of circulating tumor HPV DNA for the most prevalent HPV types that will determine if a woman has cHPVDNA

Intervention type: DIAGNOSTIC_TEST
Intervention: digital PCR (dPCR) assay
Description: It is a highly sensitive and specific droplet digital PCR assay for absolute quantification of circulating tumor HPV DNA for the most prevalent HPV types that will determine if a woman has cHPVDNA

Intervention type: DIAGNOSTIC_TEST
Intervention: digital PCR (dPCR) assay
Description: It is a highly sensitive and specific droplet digital PCR assay for absolute quantification of circulating tumor HPV DNA for the most prevalent HPV types that will determine if a woman has cHPVDNA
Study: NCT01286272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV or SC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography with Radiolabeled Targeting Agent
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography with Radiolabeled Targeting Agent
Description: Undergo FDG-PET
Study: NCT03008473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video laryngoscope and chest CT iminge

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional intubation of uniblocker
Study: NCT02465047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help booklet
Description: See Arm/Group Description
Study: NCT01148420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone 17-Acetate
Description: Medroxyprogesterone 20mg orally 3 times a day for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medroxyprogesterone acetate
Description: Depo Provera 150mg Intramuscular injection
Study: NCT04968145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home To Stay Mobile Health Application
Description: Home to stay is an integrated discharge monitoring system with a mobile application. Features of the application include a Daily Health Check to report on post-operative recovery, picture taking capability to photograph incisions/wounds and educational information on post-operative care at home.~Patients will complete a Daily Health Check on post-discharge Day #1-14, #21 and #30. The Daily Health Check consists of a series of questions specific to colorectal surgery as well as the Quality of Recovery (QoR-15) questionnaire. After completion, the participant will receive a list of recommendations tailored to their responses including relevant education modules, to contact the surgical team or in urgent cases to go to the nearest emergency room. The participants' responses will be monitored daily via a secure web site. Any participants' responses in the extreme ranges are automatically red flagged and notify the health care team that a follow up telephone call is required.
Study: NCT04026451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sedation guided by SEF95 (10-13 Hz) from SedLine® monitor
Description: Dosage of propofol and fentanyl will be guided by SEF95 value between 10-13 Hz. If SEF95 is lower than 10 Hz, the infusion rate of propofol and fentanyl will be diminished; if SEF95 is higher than 13 Hz, the infusion rate of propofol and fentanyl will be increased; and if SEF95 is between 10-13 Hz, then the infusion rate will be kept.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sedation guided by SAS scale (1-2)
Description: Dosage of propofol and fentanyl will be guided by SAS to keep a value of 1-2. If SAS is higher than 1-2, then the infusion rate of propofol and fentanyl will be increased; and if SAS is 1-2, then the infusion rate of propofol and fentanyl will be maintained.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedation guided by SAS scale (1-2)
Description: Dosage of propofol and fentanyl will be guided by SAS to keep a value of 1-2. If SAS is higher than 1-2, then the infusion rate of propofol and fentanyl will be increased; and if SAS is 1-2, then the infusion rate of propofol and fentanyl will be maintained.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deep sedation with propofol andfentanyl
Description: Propofol and fentanyl will be infused to reach a score in the SAS of 1-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep sedation with propofol andfentanyl
Description: Propofol and fentanyl will be infused to reach a score in the SAS of 1-2

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Ventilation
Description: Critically ill patients will be ventilated mechanically following the clinical indication.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Critically ill patients will be ventilated mechanically following the clinical indication.
Study: NCT01783782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIET
Description: clear liquid diet for 12 hours on the day before CE, followed by an overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol 4000 solution with simethicon
Description: patients received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of PEG solution the evening before the examination, followed always by an overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol 4000 solution with simethicon
Description: patients received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of PEG solution the evening before the examination, followed always by an overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol 4000 solution with simethicon
Description: patients received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of PEG solution the evening before the examination, followed always by an overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simethicon
Description: Patients received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simethicon
Description: Patients received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion
Study: NCT04679025

Intervention type: OTHER
Intervention: Exposure - postoperative hyperglycemia
Description: Postoperative hyperglycemia (blood or capillary glucose \> 10.0 mmol/L) within 72 hours of a surgical procedure

Intervention type: OTHER
Intervention: Exposure - postoperative hyperglycemia
Description: Postoperative hyperglycemia (blood or capillary glucose \> 10.0 mmol/L) within 72 hours of a surgical procedure
Study: NCT04132466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillation using the ASSURE wearable cardioverter defibrillator therapy delivered via a waveform delivery test system
Description: defibrillation using a 170 joule biphasic truncated exponential waveform designed for the ASSURE wearable cardioverter defibrillator
Study: NCT04986813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: 1 g of TXA in 100 ml of normal saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 100 ml
Study: NCT02444377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval training
Study: NCT00305682

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: anti-thymocyte globulin
Description: Equine ATG dose is 15 mg/kg intravenously (IV) every 12 hours for 6 doses on days -6, - 5, and -4.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: anti-thymocyte globulin
Description: Equine ATG dose is 15 mg/kg intravenously (IV) every 12 hours for 6 doses on days -6, - 5, and -4.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: anti-thymocyte globulin
Description: Equine ATG dose is 15 mg/kg intravenously (IV) every 12 hours for 6 doses on days -6, - 5, and -4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Cyclophosphamide 50mg/kg x 1 to be administered IV over 2 hours with high volume fluid flush on day -6.
Study: NCT02834442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03418207

Intervention type: PROCEDURE
Group type: OTHER
Intervention: trans-perineal template-guided mapping biopsy
Description: new super saturation of prostate biopsy technique
Study: NCT01553500

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucomannan
Description: glucomannan is administered at dosage of 5g/day in form of biscuits (6 biscuits/day)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: lifestyle intervention
Description: hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity
Study: NCT03112369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Description: An international evidence-based program (EBP) for PTSD based on exposure therapy, an oral tradition of story-telling, and use of tactile medium of natural elements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing w/Skills Training (MIST)
Description: Motivational interviewing (MI) coupled with skills training is based on enhancing motivation to change and building skills to address substance use behaviors.
Study: NCT00893581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine & Placebo
Description: Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium and Placebo
Description: Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Controls
Description: Healthy control (patients given placebo -- sugar pill intended to mimic drug)
Study: NCT02585102

Intervention type: OTHER
Group type: OTHER
Intervention: Recommended Vegetable Intake
Description: Subjects will consume vegetables in amounts recommended by the Dietary Guidelines for Americans

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Vegetable Intake
Description: Subjects will consume vegetables in their usual amount
Study: NCT01654250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NWP09
Description: Methylphenidate, variable dose, daily dosing, 1 week duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04430621

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Follicle Stimulating Hormone
Description: FSH will be administered s.c. in the morning to male healthy subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follicle Stimulating Hormone
Description: FSH will be administered s.c. in the morning to male healthy subjects
Study: NCT00795795

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preimplantation Genetic Screening
Description: Preimplantation Genetic Screening

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preimplantation Genetic Screening
Description: Preimplantation Genetic Screening

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF without PGS
Description: IVF without PGS
Study: NCT00660959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lixivaptan
Description: oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral capsule
Study: NCT03845673

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: Psyllium fiber (Konsyl; Konsyl Pharmaceuticals, Easton, Md)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bowel recipe
Description: consisted of 1 cup of unprocessed wheat bran, 1 cup of applesauce, and 1/4 cup of prune juice.
Study: NCT00148538

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance and/or Aerobic Exercise
Description: Resistance and/or Aerobic Exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance and/or Aerobic Exercise
Description: Resistance and/or Aerobic Exercise
Study: NCT01230814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)
Description: Neo-Penotran® Forte (active ingredient Metronidazole \& Miconazole Nitrate), co-formulated vaginal suppositories containing metronidazole 750 mg with miconazole 200 mg and excipients (Witepsol S 55). Witepsol S 55 is a hard fat suppository base. Such bases consist mainly of triglyceride esters of the higher saturated fatty acids along with varying proportions of mono- and diglycerides. 117 subjects receive nightly for 5 consecutive night each month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaginal suppositories, identical in appearance to the active product; contains Witepsol S 55, Titanium Dioxide and D+C yellow #10 with no metronidazole or miconazole.117 subjects receive nightly for 5 consecutive nights each month.
Study: NCT02738697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: 8\~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Follow-up
Description: Patients received just follow-up instead of adjuvant chemotherapy
Study: NCT04138082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposition to high-dB soundtrack
Description: Already stated
Study: NCT01293097

Intervention type: DRUG
Group type: OTHER
Intervention: Statin
Description: Usual care, but statin dose should not be higher than that described in exclusion criteria
Study: NCT01741545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated-Interferon-lambda

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated-Interferon-lambda
Study: NCT02759263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training
Description: Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will receive a link for downloading a web-based software program. The program will be installed on a computer at a family's home by a research assistant. Parents and adolescents will be actively involved, and during the installation session, adolescents will complete several practice trials. The 25 sessions will be completed individually by the adolescent with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the adolescent can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
Study: NCT03699800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graphomotor intervention program
Description: The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
Study: NCT03517020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Nebivolol Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forest Pharmaceuticals Inc's Bystolic Tablets
Study: NCT04928066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.

Intervention type: DRUG
Group type: OTHER
Intervention: Tofacitinib
Description: Tofacitinib,5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib,5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.

Intervention type: DRUG
Group type: OTHER
Intervention: Pred
Description: Pred, 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pred
Description: Pred, 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response.